Anita Kumar,K.S. Bantilan,A.P. Jacob,A. Park,S.F. Schoninger,C. Sauter,G.A. Ulaner,C. Casulo,M. Faham,K.A. Kong,R.K. Grewal,J. Gerecitano,A. Hamilton,P. Hamlin,M. Matasar,C.H. Moskowitz,A. Noy,M.L. Palomba,C.S. Portlock,A. Younes,T. Willis,A.D. Zelenetz

Abstract:/Background: Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Limited published data exists in MCL on the performance of next-generation sequencing (NGS)-based assay of immunoglobulin gene rearrangements for MRD assessment.s: In a prospective clinical trial (NCT01484093) with intensive induction chemotherapy and autologous stem cell transplant, post-treatment peripheral blood samples were collected from 16 MCL patients and analyzed with an earlier version of the Adaptive Biotechnologies MRD assay.Of the seven patients who remained in remission, the MRD test remained negative in 5 of 7 (71%). Of the nine patients who relapsed, the MRD test was positive at least 3 months prior to relapse in 6 patients (67%), and positive at the time of relapse in 1 patient (11%). All patients with at least 2 positive MRD tests relapsed.The NGS-MRD assay identified early molecular relapse and we observed more sensitivity in the cellular (circulating leukocytes) versus acellular (plasma cell-free DNA) compartment. This observation may be due to availability of tumor target or a limitation of the assay.

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue